R&D

Research & Development 

Mallinckrodt Pharmaceuticals' mission is Listening for Needs, Delivering Solutions. This focus is evident in our Research & Development (R&D) organization which includes medicines for acute and critical care, autoimmune and rare diseases, and pain management. We attract highly skilled professionals who are experienced and adept at managing the complex pharmaceutical environments we work in every day, and who are committed to finding solutions for the unmet needs of patients.

Mallinckrodt's Specialty Brands R&D organization’s focus includes the therapeutic areas of neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products and we have extensive capabilities and unique combinations of strengths in the following areas:

• Clinical Development & Medical Affairs – Design and execute trials with deep therapeutic and disease area expertise in conditions across our diverse businesses. Excellence in medical strategy, interactions with thought leaders and effective scientific communication.

• Research and Development Strategic Operations – Develop project plans, apply a systematic approach to science and provide expertise in execution of clinical studies and providing critical data.

• Evidence Generation & Data Sciences – Maximize capabilities in the area of Evidence Generation & Data Sciences in order to gain deeper understanding of our markets to generate both clinical and value evidence for our portfolio of products.

• Regulatory Affairs & Pharmacovigilance – Lead and navigate all regulatory processes, and Agency interactions as well as navigating the complicated terrain associated with regulatory oversight, with substantial and specialized expertise managing the production, handling and distribution of controlled substances.

Our Specialty Generics includes specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients, and manufacturing capabilities.